Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amgen, Millennium: The Takeda Oncology Company, and Takeda Pharmaceutical's MONET1 multicenter, randomized, placebo-controlled, double-blind Phase 3 trial assessing Motesanib administered in combination with Paclitaxel and Carboplatin failed to meet primary objective of showing an improvement in overall survival (OS).
Subscribe to our email newsletter
Motesanib is an investigational, orally-administered small molecule antagonist of vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptors, and stem cell factor receptor.
The trial is evaluating around 1,090 patients who are suffering from advanced non-squamous non-small cell lung cancer (NSCLC).
The adverse event profile for Motesanib was consistent with that seen in previous Motesanib studies in NSCLC.
Amgen Research and Development executive vice president Roger Perlmutte said they are disappointed with the results from this trial, but look forward to further analysis of the data which may ultimately help inform future research in this area.